Literature DB >> 25430911

The use of clinical and biological characteristics to predict outcome following First Episode Psychosis.

K Oliver Schubert1, Scott R Clark1, Bernhard T Baune2.   

Abstract

OBJECTIVE: Psychotic illnesses such as schizophrenia and other non-affective psychoses are heterogeneous in disease course and functional outcomes. We review evidence from investigations in clinical psychiatry, neuroimaging, neurocognition, and blood biomarker research suggesting that distinct bio-psycho-social patterns exist at the onset and during the early phase of a First Episode Psychosis (FEP), which can describe the risk of individual illness progression and functional trajectories.
METHOD: A selective literature review was performed on articles drawn from Medline searches for relevant key words. A simulation model was constructed from data derived from two recent publications, selected as examples of studies that investigated multivariate predictors of long-term outcome following FEP.
RESULTS: We illustrate how illness trajectories following FEP could be described based on multimodal sociodemographic, clinical, psychological, and neurobiological information. A clinical modeling simulation shows thatrisk trajectories for achieving long-term favorable or unfavorable outcomes can differ significantly depending on baseline characteristics in combination with MRI and functional measurements within 6 months of disease onset.
CONCLUSIONS: Multimodal trajectory modeling may be useful to describe longitudinal outcomes following FEP. Richlongitudinal data on predictors and outcomes, and better integration of multimodal (sociodemographic, clinical, psychological, biological) data, are required to operationalize this approach. This technique may improve our understanding of course of illness and help to provide a more personalized approach to the assessment and treatment of people presenting with FEP. © The Royal Australian and New Zealand College of Psychiatrists 2014.

Entities:  

Keywords:  Schizophrenia; first-episode psychosis; functioning; predictive modeling; trajectories

Mesh:

Substances:

Year:  2014        PMID: 25430911     DOI: 10.1177/0004867414560650

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  6 in total

1.  Clozapine and Psychosocial Function in Schizophrenia: A Systematic Review and Meta-Analysis.

Authors:  Andrew T Olagunju; Scott R Clark; Bernhard T Baune
Journal:  CNS Drugs       Date:  2018-11       Impact factor: 5.749

Review 2.  Common Data Elements for National Institute of Mental Health-Funded Translational Early Psychosis Research.

Authors:  Dost Öngür; Cameron S Carter; Raquel E Gur; Diana Perkins; Akira Sawa; Larry J Seidman; Carol Tamminga; Wayne Huggins; Carol Hamilton
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-06-29

3.  Prediction of transition from ultra-high risk to first-episode psychosis using a probabilistic model combining history, clinical assessment and fatty-acid biomarkers.

Authors:  S R Clark; B T Baune; K O Schubert; S Lavoie; S Smesny; S M Rice; M R Schäfer; F Benninger; M Feucht; C M Klier; P D McGorry; G P Amminger
Journal:  Transl Psychiatry       Date:  2016-09-20       Impact factor: 6.222

4.  Multimodal MRI assessment for first episode psychosis: A major change in the thalamus and an efficient stratification of a subgroup.

Authors:  Andreia V Faria; Yi Zhao; Chenfei Ye; Johnny Hsu; Kun Yang; Elizabeth Cifuentes; Lei Wang; Susumu Mori; Michael Miller; Brian Caffo; Akira Sawa
Journal:  Hum Brain Mapp       Date:  2020-12-30       Impact factor: 5.399

5.  Neurocognition and Social Cognition Predicting 1-Year Outcomes in First-Episode Psychosis.

Authors:  Maija Lindgren; Minna Holm; Tuula Kieseppä; Jaana Suvisaari
Journal:  Front Psychiatry       Date:  2020-12-04       Impact factor: 4.157

Review 6.  Is It Possible to Predict the Future in First-Episode Psychosis?

Authors:  Jaana Suvisaari; Outi Mantere; Jaakko Keinänen; Teemu Mäntylä; Eva Rikandi; Maija Lindgren; Tuula Kieseppä; Tuukka T Raij
Journal:  Front Psychiatry       Date:  2018-11-13       Impact factor: 4.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.